Conclusions
NSCLC, toxicities, Nab‐paclitaxel
NSCLC
Nab‐paclitaxel therapy improved ORR after PD‐(L)1 inhibitor treatment failure with a durable response of 13% and acceptable toxicities in patients with advanced NSCLC.
